These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38898427)

  • 21. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort.
    Nga HS; Palma LMP; Ernandes Neto M; Fernandes-Charpiot IMM; Garcia VD; Kist R; Miranda SMC; Macedo de Souza PA; Pereira GM; de Andrade LGM
    PLoS One; 2021; 16(11):e0258319. PubMed ID: 34748552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
    Menne J; Delmas Y; Fakhouri F; Licht C; Lommelé Å; Minetti EE; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
    BMC Nephrol; 2019 Apr; 20(1):125. PubMed ID: 30971227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States.
    Wang Y; Al-Dakkak I; Garlo K; Ong ML; Tomazos I; Mahajerin A
    Kidney Med; 2023 Aug; 5(8):100683. PubMed ID: 37415624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
    Gediz F; Payzin BK; Ecemis S; Güler N; Yilmaz AF; Topcugil F; Berdeli A
    Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
    Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
    Fakhouri F; Fila M; Hummel A; Ribes D; Sellier-Leclerc AL; Ville S; Pouteil-Noble C; Coindre JP; Le Quintrec M; Rondeau E; Boyer O; Provôt F; Djeddi D; Hanf W; Delmas Y; Louillet F; Lahoche A; Favre G; Châtelet V; Launay EA; Presne C; Zaloszyc A; Caillard S; Bally S; Raimbourg Q; Tricot L; Mousson C; Le Thuaut A; Loirat C; Frémeaux-Bacchi V
    Blood; 2021 May; 137(18):2438-2449. PubMed ID: 33270832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)?
    Menne J
    Kidney Int; 2020 Jun; 97(6):1106-1108. PubMed ID: 32444092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
    Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
    Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
    Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
    Alobaidi S; AlDabbagh A; Alamoudi A; Almowarey M; Akl A
    CEN Case Rep; 2019 May; 8(2):139-143. PubMed ID: 30715674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome.
    Levy AR; Chen P; Johnston K; Wang Y; Popoff E; Tomazos I
    J Med Econ; 2022; 25(1):249-259. PubMed ID: 35020547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
    Cugno M; Gualtierotti R; Possenti I; Testa S; Tel F; Griffini S; Grovetti E; Tedeschi S; Salardi S; Cresseri D; Messa P; Ardissino G
    J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
    Cao M; Leite BN; Ferreiro T; Calvo M; Fernández C; Alonso Á; Rodriguez A; Salvador P; Seijo R; Pita S; Arjona E; Rodríguez de Córdoba S; Valdés Cañedo F
    Am J Nephrol; 2018; 48(3):225-233. PubMed ID: 30205388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.
    Tokuyasu D; Suzuki S; Uzawa A; Nagane Y; Masuda M; Konno S; Kubota T; Samukawa M; Sugimoto T; Ishizuchi K; Oyama M; Yasuda M; Akamine H; Onishi Y; Suzuki Y; Kawaguchi N; Minami N; Kimura T; Takahashi MP; Murai H; Utsugisawa K
    Ann Clin Transl Neurol; 2024 May; 11(5):1338-1346. PubMed ID: 38572524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach.
    Laurence J
    Clin Adv Hematol Oncol; 2020 Apr; 18(4):221-230. PubMed ID: 32628650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update.
    Ardissino G; Tel F; Sgarbanti M; Cresseri D; Giussani A; Griffini S; Grovetto E; Possenti I; Perrone M; Testa S; Paglialonga F; Messa P; Cugno M
    Pediatr Nephrol; 2018 Mar; 33(3):457-461. PubMed ID: 29046944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transplantation in pediatric aHUS within the era of eculizumab therapy.
    Özçakar ZB; Ozaltin F; Gülhan B; Çomak E; Parmaksız G; Baskın E; Topaloğlu R; Kasap Demir B; Canpolat N; Yuruk Yildirim Z; Demircioğlu Kılıç B; Yüksel S; Söylemezoğlu O
    Pediatr Transplant; 2021 May; 25(3):e13914. PubMed ID: 33217100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic lupus erythematosus presenting with atypical hemolytic uremic syndrome: a case report and review of the literature.
    Smith J; Hans V; Yacyshyn E; Rouhi A; Oliver M
    Rheumatol Int; 2024 Oct; 44(10):2213-2225. PubMed ID: 38502235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.
    Asif A; Nayer A; Haas CS
    J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.